Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Assessment of Dentifrice on Periodontal Disease Biomarkers in Gingival Crevicular Fluid", in the Journal of Periodontology (2010, Vol. 81, No. 9, Pages 1273-1279). The article reports the results of a biomarker validation study carried out in collaboration with co-authors Virginia M. Barnes and colleagues of Colgate-Palmolive, a global leader in oral care. Periodontal disease, described as inflammation of the gums, is among the most common infectious diseases. Triclosan, the active ingredient in Colgate Total (CT), is a proven therapeutic agent against gingivitis. CT is the only FDA approved dentifrice for the treatment of gingivitis.
“Assessment of Dentifrice on Periodontal Disease Biomarkers in Gingival Crevicular Fluid”
The study follows previous research by Dr. Barnes and collaborators at Colgate-Palmolive Company which used Metabolon's patented global metabolomic profiling platform to identify candidate biomarkers in gingival crevicular fluid samples from subjects with chronic periodontitis. In this latest report, the biomarkers associated with gingivitis and periodontitis identified in the previous study, were validated as sensitive indicators for periodontal diseases. The levels of inosine, lysine, putrescine and xanthine correlated with the therapeutic effects of brushing with CT, a triclosan-containing dentrifice, against gingivitis and provided biochemical confirmation that CT can provide therapeutic improvement against gingivitis. These four biomarkers were significantly altered before observable clinical changes suggesting they could be useful for rapidly assessing clinical efficacy of anti-gingivitis products.
What are the capabilities of a commercially available p-tau217 immunoassay to identify Alzheimer disease pathophysiology?